Glob­al Blood Ther­a­peu­tics poised to sub­mit ap­pli­ca­tion for ac­cel­er­at­ed ap­proval, with new piv­otal da­ta on its sick­le cell dis­ease drug

Glob­al Blood Ther­a­peu­tics is set to sub­mit an ap­pli­ca­tion for ac­cel­er­at­ed ap­proval in the sec­ond-half of this year, af­ter un­veil­ing fresh da­ta from a late-stage tri­al that showed just over half the pa­tients giv­en the high­est dose of its ex­per­i­men­tal sick­le cell dis­ease drug ex­pe­ri­enced a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in oxy­gen-wield­ing he­mo­glo­bin, meet­ing the study’s main goal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER